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The adenosine  A3 receptor  (A3R) belongs to a family of four adenosine receptor (AR) subtypes 
which all play distinct roles throughout the body.  A3R antagonists have been described as 
potential treatments for numerous diseases including asthma. Given the similarity between 
(adenosine receptors) orthosteric binding sites, obtaining highly selective antagonists is a challenging 
but critical task. Here we screen 39 potential  A3R, antagonists using agonist‑induced inhibition of 
cAMP. Positive hits were assessed for AR subtype selectivity through cAMP accumulation assays. 
The antagonist affinity was determined using Schild analysis  (pA2 values) and fluorescent ligand 
binding. Structure–activity relationship investigations revealed that loss of the 3‑(dichlorophenyl)‑
isoxazolyl moiety or the aromatic nitrogen heterocycle with nitrogen at α‑position to the carbon 
of carboximidamide group significantly attenuated K18 antagonistic potency. Mutagenic studies 
supported by molecular dynamic simulations combined with Molecular Mechanics—Poisson 
Boltzmann Surface Area calculations identified the residues important for binding in the  A3R 
orthosteric site. We demonstrate that K18, which contains a 3‑(dichlorophenyl)‑isoxazole group 
connected through carbonyloxycarboximidamide fragment with a 1,3‑thiazole ring, is a specific 
 A3R (< 1 µM) competitive antagonist. Finally, we introduce a model that enables estimates of the 
equilibrium binding affinity for rapidly disassociating compounds from real‑time fluorescent ligand‑
binding studies. These results demonstrate the pharmacological characterisation of a selective 
competitive  A3R antagonist and the description of its orthosteric binding mode. Our findings may 
provide new insights for drug discovery.
Abbreviations
AR  Adenosine receptor
A1R  A1 adenosine receptor
A2AR  A2A adenosine receptor
A2BR  A2B adenosine receptor
A3R  A3 adenosine receptor
CA200645  Fluorescent xanthine amine congener
cAMP  Adenosine -3′,5′ cyclic monophosphate
CHO  Chinese hamster ovary
DMSO  Dimethyl sulfoxide
DPCPX  8-Cyclopentyl-1,3-dipropyl-7H-purine-2,6-dione
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MRS 1220  N-(9-chloro-2-furan-2-yl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide
NECA  (2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-dihydroxyoxolane-2-carboxamide
Nluc  Nano-luciferase
Nluc-A3R  NanoLuc-labelled  A3 adenosine receptor
PMA  Phorbol 12-myristate 13-acetate
MD  Molecular dynamic
MM-PBSA  Molecular Mechanics-Poisson Boltzmann Surface Area
SBDD  Structural-based drug design
vdW  Van der Waals
The adenosine  A3 receptor  (A3R), belongs to a family of four adenosine receptor (AR) subtypes  (A1R,  A2AR,  A2BR 
and  A3R), and is involved in a range of pathologies including cardiovascular, neurological and tumour-related 
diseases. Unsurprisingly therefore,  A3R is a pharmaceutical target. Interestingly, the  A3R has been described 
as enigmatic, whereby many of the effects attributed to  A3Rs are  contradictory1. Despite this,  A3R antagonists 
having been described as potential treatments of asthma, chronic obstructive pulmonary disease (COPD) and 
 glaucoma2,3, continuous research into antagonists at the  A3R are warranted. It has also been suggested that 
the  A3R is over expressed in various tumour cells suggesting it may be a viable drug target against cancer 
 proliferation4–6. While a number of novel potent and selective  A3R antagonists have been previously  described7–9, 
one of the challenges associated with the druggability of the AR family has been the targeting of individual 
subtypes with sufficient specificity to limit off-target side  effects10.
Although all AR members are activated by the endogenous agonist adenosine, the  A2AR and  A2BR are pre-
dominantly  Gs-coupled whereas  A1R and  A3R generally couple to  Gi/o. This classical pathway following  A3R 
activation and  Gi/o coupling is the inhibition of adenylate cyclase (AC) results in a decrease in cAMP levels, 
although extracellular signal-regulated kinase 1/2 (ERK1/2) activation has also been  described11.
The  A1R and  A2AR are two of the best structurally characterised G protein-coupled receptors (GPCRs), with 
multiple structures available for  both12–16, although the  A3R structure is yet to be resolved. The limited availability 
of diverse high-resolution structures of the  A3R bound to pharmacologically distinct ligands has meant there 
is a discrepancy between the capability to predict compound binding versus pharmacological  behaviour17. In 
silico screening of vast compound libraries against receptor structures, known as structural-based drug design, 
offers huge potential in the development of highly selective  ligands18. With this in mind, compounds K1-K25, 
K28 and K35, previously discovered as  A3R  ligands19, and the newly identified compounds K26, K27, K29-K34 
and K36-K39 were pharmacologically characterised as potential antagonists using  A3R-mediated inhibition 
of cAMP accumulation. Here, we describe the identification of a potent and selective  A3R antagonist, K18 
(O4-{[3-(2,6-dichlorophenyl)-5-methylisoxazol-4-yl]carbonyl}-2-methyl-1,3-thiazole-4-carbohydroximamide). 
Using molecular dynamic (MD) simulations, Molecular Mechanics—Poisson Boltzmann Surface Area (MM-
PBSA) calculations and site-directed mutagenesis, we eluded its potential binding site. Kinetic binding experi-
ments of K18 and its congener molecules K5, and K17 using a bioluminescence resonance energy transfer (BRET) 
method combined with functional assays led to the identification of important structural features of K18 for 
binding and activity. Further evaluation of this compound (and structurally related synthetic analogues) may 
afford a novel therapeutic benefit in pathologies such as inflammation and asthma.
Results
Identification of  A3R selective antagonists. We initially conducted a blinded screen of 39 compounds 
(K1–39) to identify selective  A3R antagonists some of which have previously been identified to bind  A1R,  A3R or 
 A2AR using radio-labelled  assays19. Our screen was carried out using  A3R expressing Flp-In™-Chinese hamster 
ovary (CHO) cells where adenosine-3’,5’ cyclic monophosphate (cAMP) accumulation was detected following 
a combined stimulation of 10 μM forskolin (to allow  A3R mediated  Gi/o response to be observed), 1 μM tested 
compound and the predetermined  IC80 concentration of 2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-N-ethyl-3,4-di-
hydroxyoxolane-2-carboxamide (NECA) (3.16 nM). Compound K1-39 were identified by unblinding (Table 1 
and Supplementary Table 1) and are hereinafter referred to as their denoted ‘K’ number. For the purpose of 
structure–activity relationships studies, 12 new compounds (K26, K27, K29–K34 and K36–K39) were assayed 
both functionally and through radioligand binding (Supplementary Table 1). 
Co-stimulation with 10 μM of both forskolin and NECA reduced the cAMP accumulation when compared 
to 10 μM forskolin alone and this was reversed with the known  A3R antagonist MRS 1220 (Table 1 and Sup-
plementary Fig. 1). Compounds K1, K10, K11, K17, K18, K20, K23, K25 and K32 were identified as potential 
antagonists at the  A3R through their ability to elevate cAMP accumulation when compared to forskolin and 
NECA co-stimulation. Of the nine potential  A3R antagonists, eight (excluding K11) appeared to be antagonists 
at the tested concentration of 1 μM (Supplementary Fig. 2 and Supplementary Table 2).
A number of compounds previously documented (K5, K9, K21, K22 and K24;19 or determined in this study 
(K26, K27 and K34) to have sub-micromolar binding affinities for  A3R showed no activity in our cAMP-based 
screen (Table 1, Supplementary Table 1). To ensure robustness of our functional screen, full inhibition curves of 
NECA in the presence or absence of tested compounds (1 μM or 10 μM) were constructed in  A3R Flp-In CHO 
cells (Supplementary Fig. 3, Supplementary Table 3). In this preliminary data all nine compounds (K5, K9, K11, 
K21, K22, K24, K26, K27 and K34) appeared to reduce the NECA potency at the highest tested concentration 
(10 μM) but showed no effect at 1 μM and thus appear to be low potency antagonists at the  A3R.
AR subtype selectivity and specificity. The similarity of the different ARs has the consequence 
that many compounds display reduced selectivity. Using the  A3R Flp-In CHO or CHO-K1 cells expressing  A1R, 
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Meana Mean  differenceb A3R A1R A2AR
NECA
  
60.32 ± 3.41 – ND ND ND
DMSO CH3–SO–CH3 100.00 ± 1.15  − 39.68 ND ND ND
MRS 1220
  
111.30 ± 1.65  − 50.95 ND ND ND
K1 HTS12884SC1
  
84.81 ± 4.90  − 24.49 3.10  > 100 2.67
K10 STK3005291
  
84.91 ± 5.37  − 24.59 4.49  > 60  > 60
K11 SKT3231441
  
80.78 ± 4.77  − 20.46 5.15  > 60 30
K17 SPB027341
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 A2AR or  A2BR incubated with a single high concentration of antagonist (10 μM) and increasing concentrations 
of NECA identified K1, K10, K17, K18, K25 and K32 as  A3R selective antagonists (Fig. 1). K20 and K23 were 
antagonists at both the  A1R and  A3R (Fig. 1 and Table 2). K1, K20 and K23 showed weak antagonism at the  A2AR 







Meana Mean  differenceb A3R A1R A2AR
K18 SPB027351
  
102.6 ± 2.13  − 42.27 0.89  > 100  > 100
K20 GK037251
  
97.86 ± 2.60  − 37.54 0.91 1.09 7.29
K23 GK011761
  
88.02 ± 1.70  − 27.70 1.65 1.18 4.69
K25 GK015131
  
88.66 ± 5.36  − 28.34 1.55  > 100  > 100
K32 STK323544
  
83.39 ± 5.27  − 23.07 2.40  > 100  > 100
Table 1.  Mean cAMP accumulation as measured in Flp-In CHO cells stably expressing A3R following 
stimulation with 10 μM forskolin only (DMSO) or 10 μM forskolin, NECA at the predetermined IC80 
concentration and 1 μM test compound/MRS 1220/DMSO control. Binding affinities were obtained through 
radioligand binding assays against the  A1R,  A2AR and  A3R. a cAMP accumulation mean ± SEM expressed 
as %10 μM forskolin response where n = 3 independent experimental repeats, conducted in duplicate. 
Potential antagonists were selected for further investigation based on a high mean cAMP accumulation 
(> 80%). b Difference between the mean cAMP accumulation between ‘NECA’ and each compound expressed 
as %10 μM forskolin response. c Binding affinity measured in three independent experiments and where 
indicated, previously published in Lagarias et al.19. Bold denotes binding affinity < 10 μM. 1 Indicates previously 
published in Lagarias et al.19.
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Figure 1.  Characterisation of  A3R antagonist at all AR subtypes.  A3R Flp-In CHO cells or CHO-K1 cells (2000 
cells/well) stably expressing one of the remaining AR subtypes were exposed to forskolin in the case of  Gi-
coupled  A1R and  A3R (1 μM or 10 μM, respectively) or DMSO control in the case of  Gs-coupled  A2AR and  A2BR, 
NECA and test compound (10 μM) for 30 min and cAMP accumulation detected. All values are mean ± SEM 
expressed as percentage forskolin inhibition  (A1R and  A3R) or stimulation  (A2AR and  A2BR), relative to NECA. 
n ≥ 3 independent experimental repeats, conducted in duplicate.
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Table 2.  Potency of NECA stimulated cAMP inhibition or accumulation as determined in Flp-In CHO 
or CHO-K1 cells expressing one of four ARs subtype  (A3R,  A1R,  A2AR or  A2BR). Cells stably expressing 
 A3R,  A1R,  A2AR or  A2BR were stimulated with 10 μM forskolin (in the case of  A3R and  A1R), 10 μM tested 
compound/DMSO and increasing concentrations of NECA. Data are expressed as mean ± SEM obtained in 
n = 5 independent experimental repeats, conducted in duplicate. a Negative logarithm of NECA concentration 
required to produce a half-maximal response in the absence (NECA only) or presence of 10 μM compound at 
each AR subtype. Statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) compared to ‘NECA 
only’ was determined by one-way ANOVA with Dunnett’s post-test.
pIC50/pEC50a
A3R A1R A2AR A2BR
NECA only 9.24 ± 0.1 8.98 ± 0.1 7.88 ± 0.1 7.24 ± 0.2
K1 8.01 ± 0.2**** 8.97 ± 0.1 7.12 ± 0.1**** 7.23 ± 0.2
K10 7.74 ± 0.2**** 8.82 ± 0.1 7.84 ± 0.1 7.19 ± 0.2
K17 7.59 ± 0.1**** 8.68 ± 0.1 7.76 ± 0.1 7.15 ± 0.2
K18 6.70 ± 0.1**** 8.85 ± 0.1 7.75 ± 0.1 7.10 ± 0.2
K20 7.12 ± 0.2**** 7.43 ± 0.1 **** 7.12 ± 0.1**** 7.08 ± 0.1
K23 7.72 ± 0.1**** 7.38 ± 0.1 **** 7.26 ± 0.1** 7.04 ± 0.2
K25 7.64 ± 0.1**** 9.00 ± 0.1 7.98 ± 0.1 7.22 ± 0.2
K32 7.56 ± 0.1**** 8.85 ± 0.1 7.80 ± 0.1 7.14 ± 0.2
Table 3.  IB-MECA stimulated cAMP inhibition at WT  A3R: activity of MRS 1220 and potential antagonists. 
Forskolin stimulated cAMP inhibition was measured in Flp-In-CHO stably expressing  A3R following 
stimulation with 10 μM forskolin, compound at the indicated concentration and varying concentrations of 
IB-MECA. a Negative logarithm of IB-MECA concentration required to produce a half-maximal response 
in the absence (IB-MECA only) or presence of 0.1, 1 or 10 μM compound. b Minimum cAMP accumulation 
of IB-MECA as % of the 10 μM forskolin response relative to IB-MECA only; the lower plateau of the fitted 
sigmoidal dose response curve. c The upper plateau of the fitted sigmoidal dose response curve corresponding 
to % of the 10 μM forskolin inhibition, relative to IB-MECA. d The cAMP accumulation when stimulated with 
compound at the indicated concentration and 10 μM forskolin stimulation only. e The difference between 
 Emin and basal signaling. f Value reported to determine inverse agonism: negative logarithm of compound 
concentration required to produce a half-maximal response. Data are expressed as mean ± SEM obtained in 
n separate experiments. Inverse agonist experiments were conducted in 3 separate experiments. Statistical 
significance (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) compared to ‘IB-MECA only’ was determined by 
one-way ANOVA with Dunnett’s post-test.
WT  A3R Flp-In-CHO
pIC50a Eminb Basal c True Basal d Span e n
Inverse agonism 
 pEC50f.
IB-MECA only 10.72 ± 0.1 − 8.42 ± 2.6 107.7 ± 2.6 102.2 ± 2.9 116.1 ± 3.5 27
MRS 1220
0.1 nM 10.67 ± 0.1 9.8 ± 3.5** 107.6 ± 3.7 99.7 ± 4.0 97.9 ± 4.9* 9
1 nM 9.90 ± 0.1**** 20.9 ± 3.8*** 139.0 ± 3.1**** 124.8 ± 4.1** 118.1 ± 4.8 8 9.21 ± 0.2
10 nM 8.39 ± 0.1**** 46.7 ± 4.9**** 143.6 ± 2.1**** 133.8 ± 3.6**** 96.9 ± 5.1* 8
K1
0.1 μM 10.55 ± 0.1 − 5.4 ± 4.5 117.2 ± 4.3 105.9 ± 4.3 122.5 ± 5.9 6
1 μM 10.23 ± 0.1*** 7.9 ± 4.5* 141.3 ± 3.7**** 132.0 ± 6.6**** 133.3 ± 5.6 7 4.93 ± 0.1
10 μM 9.47 ± 0.1**** 36.8 ± 4.4**** 161.3 ± 2.9**** 152.6 ± 5.4**** 124.5 ± 5.1 6
K10
0.1 μM 10.69 ± 0.1 − 5.2 ± 4.3 125.3 ± 4.0** 125.1 ± 6.3* 130.5 ± 5.6 5
1 μM 10.13 ± 0.1**** − 1.3 ± 4.4 146.7 ± 3.5**** 140.4 ± 4.2**** 148.1 ± 5.5** 5 5.81 ± 0.1
10 μM 9.12 ± 0.1**** 8.5 ± 6.4 161.1 ± 3.9**** 150.0 ± 5.8**** 152.6 ± 7.2**** 5
K17
0.1 μM 10.75 ± 0.1 − 0.9 ± 3.2 115.5 ± 3,3 111.8 ± 4.5 116.5 ± 4.5 7
1 μM 10.17 ± 0.1**** 6.5 ± 3.8 141.7 ± 3.2**** 131.7 ± 5.2**** 135.3 ± 4.8* 7 6.24 ± 0.2
10 μM 9.05 ± 0.1**** 14.83 ± 5.2*** 151.7 ± 3.0**** 143.9 ± 6.1**** 137.9 ± 5.8* 7
K18
0.1 μM 10.65 ± 0.1 5.4 ± 2.6 118.6 ± 2.6 118.5 ± 4.1 113.1 ± 3.5 6
1 μM 9.65 ± 0.1**** 10.7 ± 4.1* 140.1 ± 2.6**** 125.6 ± 5.1** 129.4 ± 4.7 6 6.84 ± 0.2
10 μM 8.38 ± 0.1**** 28.0 ± 5.9**** 147.7 ± 2.4**** 138.6 ± 2.4**** 119.7 ± 6.1 7
K25
0.1 μM 10.81 ± 0.1 7.1 ± 2.5 109.5 ± 2.5 108.9 ± 3.3 102.4 ± 3.4 6
1 μM 10.12 ± 0.1**** 6.7 ± 3.8 126.7 ± 2.9** 124.0 ± 4.1* 120.1 ± 4.6 5 6.01 ± 0.1
10 μM 9.21 ± 0.1**** 17.5 ± 3.2**** 136.6 ± 1.8**** 131.2 ± 4.1*** 119.1 ± 3.5 6
K32
0.1 μM 10.74 ± 0.1 − 0.6 ± 4.8 127.6 ± 4.9** 116.5 ± 6.0 128.2 ± 6.6 5
1 μM 9.95 ± 0.1**** 3.6 ± 4.3 146.9 ± 3.4**** 130.5 ± 5.8*** 143.3 ± 5.3** 5 6.79 ± 0.2
10 μM 9.09 ± 0.1**** 17.7 ± 5.4*** 152.3 ± 3.3**** 140.2 ± 6.9**** 134.6 ± 6.1 5
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selectivity findings agree with our previously published radioligand binding data (Lagarias et al.19) and are sum-
marised in Table 2. 
Characterisation of competitive antagonists at the  A3R. All eight  A3R antagonists were confirmed 
to antagonise (2S,3S,4R,5R)-3,4-dihydroxy-5-[6-[(3-iodophenyl)methylamino]purin-9-yl]-N-methyloxolane-
2-carboxamide (IB-MECA) (Fig. 2 and Table 3) and preliminary data suggests this extends to NECA antago-
nism (Supplementary Fig. 4 and Supplementary Table 4) in a concentration-dependent manner. Schild analysis 
characterised K1, K10, K17, K18, K20, K23, K25 and K32 as competitive antagonists at the  A3R (Schild slope not 
significantly different from unity, Fig. 2). K20 and K23 were also characterised as competitive antagonists at the 
 A1R (Supplementary Fig. 5 and Supplementary Table 5). 
When comparing the activity of  A3R selective antagonists (K10, K17, K18 and K25), K18 was the most 
potent, showed  A3R specificity and higher  A3R binding affinity (Table 2) and we propose it as our lead com-
pound. The original competition binding experiments that identified the panel of antagonist was performed 
using  [3H]2R,3R,4S,5R)-2-(2-hex-1-ynyl-6-methylaminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-
diol (HEMADO)19. To ensure the use of NECA or IB-MECA in our study did not influence characterisation of 
the compounds, we assessed the ability of K18 to antagonise cAMP inhibition by HEMADO at the  A3R, and 
compared its potency to K17 (Supplementary Fig. 6 and Table 4). In this exploratory data, K18 again displayed 
higher potency than K17 at the  A3R.
In addition, we wanted to determine if K18 could also antagonise the activity of the  A3R when an alternative 
downstream signalling component was measured; ERK1/2 phosphorylation (Fig. 3). In line with previously 
reported  findings11,20, agonists at the  A3R increased ERK1/2 phosphorylation after 5 min, with IB-MECA tenfold 
more potent than NECA (Supplementary Fig. 9) and preliminary data suggests this was entirely  Gi/o-mediated 
(pERK1/2 levels were abolished upon addition of PTX). K18 was able to antagonise  A3R-mediated phospho-
rylation of ERK1/2 with the antagonist potency  (pA2 values) not significantly different compared to the cAMP-
inhibition assay (Fig. 3C).
A3R constitutive activity and inverse agonism. We next determined if any of our competitive antago-
nist could function as inverse agonists of the  A3R. In our hands, the  A3R, when expressed in Flp-In-CHO cells, 
displays constitutive activity (Supplementary Fig. 7). All eight characterised  A3R antagonists showed a concen-
tration-dependent inverse agonism of the  A3R when compared to DMSO control (Fig. 2) and were determined 
to be  A3R dependent (Supplementary Fig. 8). This was also found to be the case for K20 and K23 at the  A1R 
(Supplementary Fig. 5). Notably, DMSO showed a concentration-dependent elevation in cAMP accumulation 
above that of forskolin alone.
Evaluation of the binding mode of K18 at  A3R. We have previously investigated the binding mode of 
K18 at the human  A3R using a homology model of the human  A3R and  simulations21. The computational model 
showed that the 3-(dichlorophenyl) group is positioned close to  V1695.30,  M1775.40,  I2496.54 and  L2647.34 of the 
 A3R orthosteric binding site forming attractive vdW interactions. The amino group of the ligand is hydrogen-
bonded to the amido group of  N2506.55. The isoxazole ring is engaged in an aromatic π-π stacking interaction 
with the phenyl group of  F1685.29 (Fig. 4). The thiazole ring is oriented deeper into the receptor favouring inter-
actions with  L2466.51,  L903.32 and  I2687.39 (for full details  see19).
Of the identified residues predicted to mediate an interaction between K18 and the  A3R, the ones which 
showed -according to the molecular dynamic (MD) simulations- the most frequent and the most important 
contacts were chosen for investigation and included amino acids  L903.32,  F1685.29,  V1695.30,  M1775.40,  L2466.51, 
 I2496.54,  N2506.55,  L2647.34 and  I2687.39 (Fig. 4). Site-directed mutagenesis was performed replacing each residue 
with an alanine in the  A3R and expressed in the Flp-In-CHO™ cells lines. Each mutant was then screened for 
their ability to suppress forskolin-induced cAMP accumulation in response to NECA/IB MECA stimulation in 
the presence and absence of K18 and the detailed results are presented in Table 5 and Fig. 5. Mutation of resi-
dues  F1685.29,  L2466.51,  N2506.55 and  I2687.39 abolished agonist induced suppression of forskolin-induced cAMP 
accumulation and were discontinued in this  study22. The affinity  (pA2) of K18 at the WT and mutant  A3R were 
compared in order to determine the potential antagonist binding site (Fig. 5, Table 5). As described  previously21, 
K18 displayed no difference in affinity at  I249A6.54 (compared to WT), whereas  M177A5.40 and  V169A5.30 were 
significantly smaller. Interestingly, we found an increase in the affinity for  L90A3.32 and  L264A7.34 when compared 
to WT. As would be expected, the K18 affinity at the  A3R mutants was not different between agonists, confirm-
ing agonist independence (Supplementary Fig. 11). These experimental findings are reflected in our predicted 
binding pose of K18 at the WT  A3R (Fig. 4)21. 
We further investigated the suggested binding mode through comparatively modelled K5 and K17 binding at 
the  A3R given their structural similarity with K18; K17 and K18 possess one and two chlorine atoms attached to 
the phenyl ring of the 3-phenyl-isoxazole moiety, respectively, whereas K5 has none (Fig. 4B,C). The suggested 
binding mode of K18 was further verified since the MM-PBSA calculated rankings in binding free energies 
were in agreement with experimental differences in binding affinities using radio-labelled assays and BRET 
(K5 < K17 < K18 < MRS 1220—Table 6) and antagonistic potencies with 5 having no chlorine atoms in 3-phenyl-
isoxazolyl lacking any antagonistic potency. Finally, following MD simulations of compounds K26, K27, K29-K34 
and K36-K39, we observed that K26 (and K34 for that matter) displayed a similar binding pose (Supplementary 
Fig. 10) to that of K18 (Fig. 4). K26, K34, K5, K17 and K18 have all similar binding affinities, measured by radio-
labelled assays (Sup. Table 1). K26 and K34 contain the o-diphenyl-carbonyl instead of the 3-phenyl-isoxazole 
moiety in K5 but all three functionally showed weak antagonistic potency (> 1 μM, Supplementary Fig. 3), in con-
trast to K18 or K17 which contain a 3-(chlorophenyl)-isoxazolyl moiety or 3-(dichlorophenyl)-isoxazolyl moiety, 
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Figure 2.  IB-MECA stimulated cAMP inhibition at WT  A3R: activity of N-(9-chloro-2-furan-2-yl-[1,2,4]
triazolo[1,5-c]quinazolin-5-yl)-2-phenylacetamide (MRS 1220) and potential antagonists. Flp-In-CHO cells 
(2000 cells/well) stably expressing WT  A3R were exposed to forskolin 10 μM, IB-MECA and test compound/
MRS 1220/DMSO control for 30 min and cAMP accumulation detected. (A) Representative dose response 
curves are shown as mean ± SEM expressed as percentage forskolin inhibition (10 μM) relative to IB-MECA. 
Key indicated in K1 is identical for all ‘K’ test compounds shown. (B)  pIC50 values for individual repeats 
including half-log concentration are shown as mean ± SEM. (C) Schild analysis of data represented in (A) and 
(B). A slope of 1 indicates a competitive antagonist. The x-axis is expressed as − log (molar concentration of 
antagonist) giving a negative Schild slope. (D) Inverse agonism at the  A3R. cAMP accumulation following 
a 30-min stimulation with forskolin (10 μM) and increasing concentrations of antagonist/DMSO control 
was determined in WT  A3R expressing Flp-In-CHO cells. Representative dose response curves are shown as 
mean ± SEM expressed as percentage forskolin (10 μM), relative to IB-MECA.
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respectively. These findings suggest that a more complex binding mode is present which will be investigated in the 
future, through synthetic installation of chlorine atoms in the ended phenyl ring of o-diphenyl-carbonyl moiety.
Kinetics of  A3R antagonists determined through BRET. NanoBRET techniques have been success-
fully used to determine the real-time kinetics of ligand binding to  GPCRs23–25. Here, we investigated the ability of 
the selective  A3R antagonists MRS 1220, K17 or K18 to inhibit specific binding of the fluorescent  A3R antagonist 
CA200645 to Nluc-A3R26,27. The kinetic parameters for CA200645 at Nluc-A3R were initially determined as  Kon 
(k1) = 2.86 ± 0.89 × 107  M−1  min−1,  Koff (k2) = 0.4397 ± 0.014  min−1 with a  KD of 17.92 ± 4.45  nM. (Supplemen-
tary Fig. 12). Our MRS 1220 kinetic data was fitted with the original ‘kinetic of competitive binding’  model28 
(built into GraphPad Prism 8.0) with a determined  Kon (k3) and  Koff (k4) rate of 3.25 ± 0.28 × 108 M−1 min−1 and 
0.0248 ± 0.005 min−1, respectively. This gave a residence time (RT) (RT = 1/Koff) of 40.32 min. It was noticed in 
the analysis for K5, K17 and K18 that the fit in some cases was ambiguous and/or the fitted value of the com-
pound dissociation rate constant was high (k4 > 1 min−1, corresponding to a dissociation t1/2 of < 42 s). In order to 
determine the reliability of the fitted k4 value, data were also analysed using an equation that assumes compound 
dissociation is too rapid for the dissociation rate constant to be determined reliably and the fits to the two equa-
tions were compared (“Kinetics of competitive binding, rapid competitor dissociation”, derived in the Appendix 
I). This model allowed estimate of the equilibrium binding affinity of the compound (Ki) but not the binding 
kinetics of K5, K17 and K18 (Fig. 6 and Table 6). These affinity values were in agreement with those obtained via 
Schild analysis (except for K5) and were approximately tenfold higher than those determined through radioli-
gand binding (Table 6). Notably, the order of affinity (K5 < K17 < K18) was consistent.
Assessing the species selectivity of  A3R antagonists. There remains an issue as to understanding the 
precise role of the  A3R. This is, in part due, to a lack of appropriate antagonists that are able to be tested in classi-
cal animal models such as rodent since only a few molecules (including the 6-phenyl-1,4-dihydropyridine MRS 
1191 and the triazoloquinazoline MRS 1220) display cross species (human and rat)  reactivity29. Comparison of 
residues of the binding area between human and rat  A3R show that they differ in residues  1675.28,  1695.30,  1765.37, 
Table 4.  Binding of compounds to the rat  A3R. Equilibrium dissociation constant of MRS 1220 and K 
compounds as determined through NanoBRET ligand-binding  (pKi).
pKi n
MRS 1220 6.74 ± 0.04 5
K1 6.07 ± 0.05 5
K10 4.19 ± 0.09 3
K17 4.60 ± 0.09 3
K18 4.60 ± 0.04 3
K20 5.71 ± 0.03 5
K23 5.93 ± 0.04 5
K25 6.37 ± 0.06 5
K32 4.05 ± 0.10 3
Figure 3.  A3R constitutive activity and inverse agonism. K18 also reduced levels of agonist stimulated ERK1/2 
phosphorylation. pERK1/2 was detected in Flp-In-CHO cells stably expressing  A3R (2000 cells/well) stimulated 
for 5 min with (IB-MECA), with or without K18. (A) Representative dose response curves for IB-MECA 
with K18 at the indicated concentration or DMSO control shown as mean ± SEM expressed as % 1 μM PMA 
response. (B)  pEC50 values for individual repeats are shown as mean ± SEM. (C) Schild analysis of data 
represented in (A) and (B).
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 2536.58,  2647.34 (Fig. 7). The scarcity of rat  A3R antagonists prompted us to investigate if our characterised com-
pounds were also potential antagonists at the rat  A3R. Using a Nluc-tagged rat  A3R expressing HEK 293 cell line, 
we conducted NanoBRET ligand-binding experiments whereby we determined the ability of our compounds to 
inhibit specific binding of the fluorescent antagonist AV039 to Nluc-rat  A3R. As expected, AV039 was displaced 
by increasing concentrations of MRS 1220  (pKi 6.788 ± 0.1) (Fig. 7 and Table 4). We found very weak binding of 
K17, K18, K10 and K32, with no binding detected below the concentration of 10 μM, whereas K1, K20, K23 and 
K25 were determined as potential rat  A3R antagonists  (pKi 6.07 ± 0.04, 5.71 ± 0.03, 5.93 ± 0.04 and 6.37 ± 0.06, 
respectively) (Fig. 7 and Table 4). K25 had a higher binding affinity for the rat  A3R when compared to the human 
 A3R (Table 1) (pKi 6.37 ± 0.1 and 5.81, respectively).
MD simulations of the rat  A3R (performed as described previously for the human  A3R) suggested that the 
presence of  M2647.34 most likely hampers K18 binding due to steric hindrance of the dichloro-phenyl group 
(Fig. 7). In contrast, MD simulations of K25 against rat  A3R showed the formation of stable complex (Fig. 7). 
Here, the 2-amido group of the thiophene ring is hydrogen-bonded to the amido group of  N2506.55. The thio-
phene ring forms aromatic π-π stacking interaction with  F1685.29 and the 5-(p-chlorophenyl) is oriented deep in 
Figure 4.  Orthosteric binding area average structure of WT  A3R in complex with K5, K17 and K18 from MD 
simulations with Amber14ff. Side (A), top (D) view of K5 complex; side (B), top (E) view of K17 complex; side 
(C), top (F) view of K18 complex. Side chains of critical residues for binding indicated from the MD simulations 
are shown in sticks. Residues  L903.32,  V1695.30,  M1775.40,  I2496.54 and  L2647.34, in which carbon atoms are shown 
in grey, were confirmed experimentally; in residues  F1685.29,  L2466.51,  I2687.39 and  N2506.55 carbon atoms are 
shown in magenta; nitrogen, oxygen and sulfur atoms are shown in blue, red and yellow respectively.
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the binding area making contacts with  L903.32,  L2466.51 and  W2436.48.  M2647.34 forces the large lipophilic moiety 
of the thiophene ring (3-NHCOCH2SPh(CF3)2) of K25 to locate close to TM2 favouring contacts with  A692.61, 
 V722.64, and  I2687.39 (Fig. 7).
Pharmacokinetic assessments of K18. The metabolic in vitro t1/2 (human liver microsomes, 0.1 mg/
mL) of K18 (0.1 μM) was determined (0–60 min) as 24 min and the intrinsic clearance  (CLint) calculated as 
287.2 μl/min/mg (Supplementary Fig. 13). This was comparable to the reference compound verapamil and ter-
fenadine (0.1 μM) with t1/2 determined as 35 and 12 min and  CLint as 200.1 or 581.1 μl/min/mg, respectively. 
Human plasma stability assessment determined the percentage of K18 (1 μM) remaining after 120 min as 90%, 
with a t1/2 of > 120 min. This is considerably higher than the reference compound propantheline (1 μM) which 
was determined to have a half-life of 55 min. The t1/2 of K18 (1 μM) in PBS (pH 7.4) over 240 min was deter-
mined as > 240 min, with 87% remaining at 240 min and was comparable to the reference compound propanthe-
line (1 μM), with a determined t1/2 of > 240 min.
Discussion
The search for an AR subtype specific compound often leads to compounds active at more than one of the AR 
subtypes because of the broad and similar orthosteric binding site of  ARs30. Given that AR subtypes play distinct 
roles throughout the body, obtaining highly specific receptor antagonists and agonists is crucial. The virtual 
Table 5.  Antagonistic potency of K18 at  A3R mutants. cAMP accumulation as measured in Flp-In-CHO 
cells stably expressing WT or mutant  A3R following stimulation with 10 μM forskolin, varying concentrations 
of IB-MECA and ±K18 at the indicated concentration. Data are expressed as mean ± SEM obtained in n 
separate experiments. All individual experiments were conducted in duplicate. ND indicates an incomplete 
dose response curve due to the increased potency of K18 at this mutant. a Negative logarithm of IB-MECA 
concentration required to produce a half-maximal response. b Minimum cAMP accumulation of IB-MECA 
as %100 μM forskolin. The lower plateau of the fitted sigmoidal dose response curve. c The upper plateau of 
the fitted sigmoidal dose response curve corresponding %100 μM forskolin. d The cAMP accumulation when 
stimulated with 10 μM forskolin only + DMSO/K18 at the indicated concentration. e The difference between 
 Emin and basal signalling. Statistical significance (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) compared to 
WT IB-MECA stimulation ± K18 at each indicated concentration was determined by one-way ANOVA with 
Dunnett’s post-test.
pIC50a Eminb Basalc True  basald Spane n
+ DMSO
WT 10.73 ± 0.1 35.0 ± 1.6 60.1 ± 0.9 57.7 ± 1.3 25.1 ± 2.0 11
L90A 9.03 ± 0.1**** 43.3 ± 3.2 73.2 ± 2.7*** 71.5 ± 2.9*** 29.9 ± 1.8 8
V169A 11.33 ± 0.1**** 30.9 ± 1.7 55.3 ± 2.4 54.1 ± 2.5 24.3 ± 2.1 10
M177A 7.65 ± 0.1**** 38.6 ± 2.7 70.2 ± 2.0* 66.7 ± 1.8 31.6 ± 2.0 7
I249A 10.76 ± 0.1 34.9 ± 2.2 62.6 ± 2.7 59.9 ± 2.6 27.7 ± 1.3 11
L264A 10.53 ± 0.1 41.1 ± 2.2 72.0 ± 2.3** 70.8 ± 2.6** 30.9 ± 2.2 9
+ 0.1 μM K18
WT 10.64 ± 0.1 37.3 ± 1.8 63.0 ± 2.2 61.8 ± 2.6 25.8 ± 0.9 5
L90A 7.88 ± 0.1**** 50.2 ± 3.4* 77.2 ± 2.6** 74.9 ± 2.8* 27.0 ± 3.1 7
V169A 11.11 ± 0.1 * 31.9 ± 1.8 62.6 ± 2.2 60.6 ± 3.1 30.6 ± 2.1 7
M177A 7.69 ± 0.1**** 38.8 ± 2.5 70.9 ± 2.4 68.7 ± 2.3 32.1 ± 1.9 5
I249A 10.65 ± 0.1 35.6 ± 3.1 68.5 ± 3.3 67.0 ± 3.4 32.9 ± 1.3 8
L264A 9.86 ± 0.1*** 45.7 ± 2.0 79.7 ± 2.7** 77.7 ± 3.0** 34.0 ± 2.8 7
+ 1 μM K18
WT 9.65 ± 0.1 38.3 ± 2.4 67.4 ± 1.5 63.0 ± 1.8 29.1 ± 2.0 6
L90A 6.61 ± 0.1**** 54.3 ± 3.6** 76.7 ± 3.2 73.5 ± 3.1 22.4 ± 2.6 8
V169A 10.40 ± 0.1**** 31.9 ± 2.3 68.8 ± 1.7 66.5 ± 2.0 36.9 ± 2.5 7
M177A 7.27 ± 0.1**** 40.0 ± 3.5 71.4 ± 2.4 66.3 ± 2.5 31.4 ± 2.0 5
I249A 9.78 ± 0.1 36.9 ± 3.2 76.3 ± 3.7 73.1 ± 3.8 39.3 ± 2.1* 8
L264A 8.80 ± 0.1**** 47.9 ± 2.7 83.6 ± 2.1*** 79.8 ± 2.4** 35.7 ± 3.0 8
+ 10 μM K18
WT 8.38 ± 0.2 45.1 ± 1.7 72.0 ± 1.5 68.9 ± 1.6 26.9 ± 1.3 7
L90A ND 59.9 ± 2.9** 81.7 ± 2.3 78.1 ± 2.4 22.8 ± 2.0 5
V169A 9.44 ± 0.1**** 33.5 ± 1.8** 71.8 ± 1.6 69.2 ± 1.5 38.3 ± 2.0* 8
M177A 6.12 ± 0.2**** 45.7 ± 3.2 72.1 ± 2.3 67.6 ± 2.4 26.6 ± 1.6 5
I249A 8.55 ± 0.2 36.6 ± 2.1* 78.0 ± 4.2 74.7 ± 4.2 38.7 ± 3.6* 8
L264A 7.98 ± 0.1 49.1 ± 3.1 85.4 ± 2.7* 82.8 ± 2.6** 33.7 ± 5.0 5
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Figure 5.  IB-MECA stimulated cAMP inhibition at WT or mutant  A3R with increasing concentrations of 
K18. Flp-In-CHO cells (2000 cells/well) stably expressing WT or mutant  A3R were exposed to forskolin 10 μM, 
IB-MECA and K18 at varying concentrations for 30 min and cAMP accumulation detected. (A) Representative 
dose response curves are shown as mean ± SEM expressed as percentage maximum forskolin response (100 μM). 
(B)  pIC50 values for individual repeats including half-log concentration are shown as mean ± SEM. (C) Schild 
analysis of data represented in (A) and (B).
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screening described by Lagarias et al.19 used a combination of a ligand-based and structure-based strategies based 
upon the experimental structure of  A2AR in complex with the selective antagonist/inverse agonist  ZM24138531 
(PDB ID  3EML32), which has little affinity for  A3R and 500- to 1000-fold selectivity for  A2AR over  A1R. Although, 
our high hit rate for  A3R selective antagonist appears counter-intuitive, since the ligand-based virtual screen-
ing tool Rapid Overlay of Chemical Structures (ROCS) was used to predict structures similar to ZM241385,19.
Here, we present the pharmacological characterisation of eight  A3R antagonists identified though virtual 
screening. Of these eight compounds, K10, K17, K18, K20, K23, K25 and K32 were determined to be competi-
tive. Whereas K20 and K23 are antagonists at both the  A1R and  A3R, K10, K17, K18, K25 and K32 were are A3R 
selective antagonists. Indeed, we found no functional activity, or indeed binding affinity (< 30 μM), at the other 
AR subtypes. K1, K20 and K23 showed weak antagonism of the  A2AR with no activity at the  A2BR (Fig. 1, Table 2). 
These selectivity findings are in agreement with our radioligand binding data (Supplementary Table 1, and 
Lagarias et al.19 for K1–25, K28 and K35). However, a number of compounds previously determined to have 
micromolar binding affinity for  A3R (K5, K9, K21, K22, K24, K26, K27 and K34), show no antagonistic potency 
in our initial functional screen. Further testing confirmed that these compounds are low potency antagonists 
and, although supporting the previously published radioligand binding data, confirmed the need for functional 
testing: not all compounds with binding affinity show high functional potency.
We show the  A3R, when expressed in Flp-In-CHO cells, displays constitutive activity. Compounds which pref-
erably bind to the inactive (R) state, decreasing the level of constitutive  activity33 and in the case of a  Gi/o-coupled 
GPCR leading to an elevated cAMP, are referred to as inverse agonists. In this study all the  A3R antagonists 
identified and both  A1R antagonists (K20 and K23) were found to act as inverse agonists. We also report an 
elevation in cAMP accumulation when cells were stimulated with DMSO, which is concentration-dependent. 
Given that even low concentrations of DMSO have been reported to interfere with important cellular  processes34, 
the interpretation of these data should be made with caution.
We show that the presence of a chloro substituent in the phenyl ring of 3-phenyl-isoxazole favoured  A3R 
affinity, as following 0Cl < 1Cl < 2Cl i.e. K5 < K17 < K18. This theory is supported by both radioligand binding, 
NanoBRET ligand-binding and functional data. Moreover, MD simulations show that these compounds adopt 
a similar binding mode at the  A3R orthosteric binding site, but the free-energy MM-PBSA calculations show 
that K18, having two chlorine atoms and an increased lipophilicity, leaves the solution state more efficiently and 
enters the highly lipophilic binding area. Importantly, substitution of the 1,3-thiazole ring in K17 with either a 
2-pyridinyl ring (K32) or a 3-pyridinyl ring (K10) but not a 4-pyridinyl ring (K11) maintains  A3R antagonis-
tic potency. Also, substitution of 1,3-thiazole ring in K17 with the p-iodo-phenyl in K9 loses the antagonistic 
potency. Although we have not directly determined the effects of similar pyridinyl ring substitutions on the 
higher affinity antagonist K18, we suspect there would be no significant increase in the potency of K18 given 
the small changes we observed for K17.
For the first time, we demonstrated the utilisation of a new model which expands on the ‘Kinetic of competi-
tive binding’  model28 (built into Prism 8.0) for fitting fast kinetics data obtained from NanoBRET experiments 
and assumes the unlabelled ligand rapidly equilibrates with the free receptor. Very rapid competitor dissociation 
can lead to failure of the fit, eliciting either an ambiguous fit (regression with Prism 8: “Ambiguous”, 2019) or 
unrealistically large  K3 and  K4 values. Whereas we were able to successfully fit the MRS 1220 kinetic data with the 
Motulsky and Mahan model due to its slow dissociation, fitting of K5, K17 and K18 kinetic data with this model 
often resulting in an ambiguous fit. Our new model, assuming fast compound dissociation, successfully fits the 
data and allows the determination of binding affinity. In the cases where the data were able to fit the Motulsky 
and Mahan model, the dissociation constant was higher (of the order of 1 min−1), indicating rapid dissociation. 
Although we found nearly a tenfold difference in determined binding affinity for MRS 1220, K5, K17 and K18 
Table 6.  Binding of K5, K17, K18 and MRS 1220 to the  A3R orthosteric binding area. Effective binding 
energies (ΔGeff) and energy components (EvdW, EEL, ΔGsolv) in kcal  mol−1 calculated using the MM-PBSA 
method. a vdW energy of binding calculated using molecular mechanics. b Electrostatic energy of binding 
calculated using molecular mechanics. c Difference in solvation energy between the complex, the protein 
and the ligand, i.e. Gcomplex, solv—(Gprotein, solv + Gligand, solv). d Effective binding free energy calculated as 
ΔGeff = ΔEΜΜ + ΔGsol; in Table 6, ΔEΜΜ = ΕvdW + EEL (see “Materials and methods”). e Equilibrium dissociation 
constant of MRS 1220, K5, K17 and K18 as determined through three independent experimental approaches: 
Schild analysis  (pKB), NanoBRET  (pKi) or radioligand binding  (pKi). f pKB obtained through Schild analysis 
in  A3R stably expressing Flp-In CHO cells. g pKi (mean ± SEM) obtained in NanoBRET binding assays using 
Nluc-A3R stably expressing HEK 293 cells and determined through fitting our “Kinetics of competitive 
binding, rapid competitor dissociation” model or in the case of MRS 1220 through fitting with the ‘Kinetics 
of competitive binding’ model with a determined  Kon (k3) and  Koff (k4) rate of 3.25 ± 0.28 × 108 M−1 min−1 and 
0.0248 ± 0.005 min−1, respectively. h pKi values previously published for K5, K17 and K18 (Lagarias et al., 2018) 
or MRS 1220 (Stoddart et al., 2015) through radioligand binding assays.
EvdWa EELb ΔGsolvc ΔGeffd
pKB/pKie
Schild  analysisf NanoBRETg Radioligand  bindingh
MRS 1220 – 64.6 ± 2.6 – 11.5 ± 2.5 39.2 ± 2.4 – 36.9 ± 3.6 10.07 9.99 ± 0.04 8.2–9.2
K5 – 42.0 ± 2.7 – 9.6 ± 5.2 30.8 ± 4.3 – 20.8 ± 4.3 ND 6.06 ± 0.09 5.02
K17 – 47.0 ± 2.4 – 8.8 ± 2.7 29.8 ± 2.9 – 25.9 ± 3.6 6.35 6.33 ± 0.03 5.38
K18 – 46.3 ± 2.9 – 7.5 ± 2.4 26.9 ± 3.1 – 26.9 ± 2.7 7.20 6.92 ± 0.10 6.05
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between BRET ligand binding and radioligand binding assays, we demonstrated the order of affinity remains 
consistent. Indeed, this is seen across all three experimental approaches: Schild analysis, NanoBRET ligand-
binding assay and radioligand binding.
Combining MD simulations with mutagenesis data, we presented a final binding pose of K18 which appears 
to be within the orthosteric binding site, involving residues previously described to be involved in binding of 
 A3R  compounds35. We previously  reported22 no detectable  Gi/o response following co-stimulation with forskolin 
and NECA or IB-MECA for  A3R mutants  F168A5.29,  L246A6.51,  N250A6.55 and  I268A7.39 and our findings are 
in line with previous mutagenesis studies investigating residues important for agonist and antagonist binding 
at the human  A3R36,37. Through performing Schild analysis (results of which were used to inform modelling in 
Lagarias et al.21) we experimentally determined the effect of receptor mutation on antagonist affinity for  L90A3.32, 
V169A/E5.30,  M177A5.40,  I249A6.54 and  L264A7.34  A3R. The  pA2 value for  I249A6.54  A3R is similar to WT, whereas 
 M177A5.40 and  V169A5.30 are significantly smaller suggesting these residues appear to be involved in K18 binding. 
Interestingly we found an increase in K18 affinity at  L90A3.32 and  L264A7.34 when compared to WT. Our detailed 
MD simulations, results published  elsewhere21 have investigated the selectivity profile of K18 and have demon-
strated that K18 failed to bind  A1R and  A2AR due to a more polar area close to TM5, TM6 when compared to  A3R.
We have also performed a preliminary pharmacokinetic assessment of K18 to assess its potential as a lead 
compound for future use in drug design. Based upon our initial findings K18 has a metabolic half-life and 
intrinsic clearance equivalent to verapamil and terfenadine. K18 is highly stable in human plasma. As such these 
Figure 6.  Inhibition of BRET between Nluc and CA200645 at the  A3R by K5, K17, K18 and MRS 1220. 
HEK293 cells stably expressing Nluc-A3R were treated with 5 nM CA200645 and increasing concentrations 
of unlabelled compound (represented in nM) (A) K5, (B) K17, (C) K18 or (D) MRS 1220. For MRS 
1220, this trace demonstrates a classic tracer ‘overshoot’, as has been previously described observed when 
the unlabelled compound has a slower off rate than the labelled CA200645  (Koff of 0.0248 ± 0.005  min−1 
and 0.4397 ± 0.014 min−1 respectively) (Sykes et al.24, Motulsky and  Mahan28). The data shown are representative 
of three independent experimental repeats (mean ± SEM) fitted with the appropriate model, as determined by 
statistical comparison between our new model (“Kinetics of competitive binding, rapid competitor dissociation”, 
derived in the Appendix I) (K5, K17 and K18) or the ‘kinetic of competitive binding’ model (built into Prism) 
for MRS 1220 (see “Materials and methods” for fitting procedure and statistical comparison method). (E) 
The resulting concentration dependent decrease in BRET ratio at 10 min was taken to calculate  pKi through 
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studies suggest K18 is an ideal candidate for future investigations although a more detailed pharmacokinetic 
assessment is required.
Antagonists that are  A3R-selective across species or at rat  A3R alone are useful pharmacological tools to 
define the role of these receptors. The human and rat  A3R display 72%  homology38. The lack of rat  A3R selective 
antagonists prompted us to investigate if our characterised  A3R antagonists are potential antagonists at the rat 
 A3R. We reported no binding of our lead  A3R antagonist, K18, at the rat  A3R and MD simulations suggest this 
is due to steric hinderance by  M2647.34. This finding suggests that K18 may not only be  A3R specific within the 
human ARs but may also be selective across species. Of the compounds that showed rat  A3R binding (K1, K20, 
K23 and K25), K25 show the highest binding affinity and represents an interesting candidate for further investi-
gation. MD simulations show K25 forms a stable complex with rat  A3R and we suggest a potential binding pose.
In conclusion, we present findings of a unique scaffold (K18) which is both chemically and metabolically 
stable and as such can be used as a starting point for detailed structure–activity relationships and represents a 
useful tool that warrants further assessment. Furthermore, we introduce K25 as a potential rat  A3R antagonist 
which also warrants further investigation.
Materials and methods
Cell culture and transfection. Cell lines were maintained using standard subculturing routines as guided 
by the European Collection of Cell Culture (ECACC) and checked annually for mycoplasma infection using an 
EZ-PCR mycoplasma test kit from Biological Industries (Kibbutz Beit-Haemek, Israel). All procedures were 
performed in a sterile tissue culture hood using aseptic technique and solutions used in the propagation of each 
cell line were sterile and pre-warmed to 37 °C. All cells were maintained at 37 °C with 5%  CO2, in a humidified 
atmosphere. This study used CHO cell lines as a model due to the lack of endogenous AR subtype expression 
(Brown et al. 2008). CHO-K1-A1R, CHO-K1-A2AR, CHO-K1-A2BR and CHO-K1-A3R cells were routinely cul-
tured in Hams F-12 nutrient mix (21,765,029, Thermo Fisher Scientific) supplemented with 10% Foetal bovine 
serum (FBS) (F9665, Sigma-Aldrich). Flp-In-CHO cells purchased from Thermo Fisher Scientific (R75807) 
were maintained in Hams F-12 nutrient mix supplemented with 10% FBS containing 100 μg/mL Zeocin Selec-
tion Antibiotic (Thermo Fisher Scientific).
Stable Flp-In-CHO cell lines were generated through co-transfection of the pcDNA5/FRT expression vector 
(Thermo Fisher Scientific) containing the gene of interest and the Flp recombinase expressing plasmid, pOG44 
(Thermo Fisher Scientific). Transfection of cells seeded in a T25 flask at a confluency of ≥ 80% was performed 
using TransIT-CHO Transfection Kit (MIR 2174, Mirus Bio), in accordance with the manufacturer’s instructions. 
Here, a total of 6 μg of DNA (receptor to pOG44 ratio of 1:9) was transfected per flask at a DNA:Mirus reagent 
ratio of 1:3 (w/v). 48 h post-transfection, selection using 600 μg/mL hygromycin B (Thermo Fisher Scientific) 
(concentration determined through preforming a kill curve) was performed for two days prior to transferring 
the cells into a fresh T25 flask. Stable Flp-In-CHO cell lines expressing the receptor of interest were selected using 
600 μg/mL hygromycin B whereby the media was changed every two days. Successful mutant cell line generation 
for non-signalling mutants were confirmed by Zeocin sensitivity (100 μg/mL).
The Nluc-tagged human  A3R expressing HEK 293 cell line along with the Nluc-tagged rat  A3R 
pcDNA3.1 + construct for the generation of stable Nluc-tagged rat  A3R expressing HEK 293 cells were kindly 
gifted to us by Stephen Hill and Stephen Briddon (University of Nottingham). HEK 293 cells in a single well 
of 6-well plate (confluency ≥ 80%) were transfected with 2 μg of DNA using polyethyleneimine (PEI, 1 mg/ml, 
MW = 25,000 g/mol) (Polysciences Inc) at a DNA:PEI ratio of 1:6 (w/v). Briefly, DNA and PEI were added to 
separate sterile tubes containing 150 mM sodium chloride (NaCl) (total volume 50 μl), allowed to incubate at 
room temperature for 5 min, mixing together and incubating for a further 10 min prior to adding the combined 
mix dropwise to the cells. 48 h post-transfection, stable Nluc-rat  A3R expressing HEK 293 cell were selected 
using 600 μg/mL Geneticin (Thermo Fisher Scientific) whereby the media was changed every two days. HEK 
293 cell lines were routinely cultured in DMEM/F-12 GlutaMAX (Thermo Fisher Scientific) supplemented with 
10% FBS (F9665, Sigma-Aldrich).
Constructs. The human  A3R originally in pcDNA3.1 + (ADRA3000000, cdna.org) was cloned into the 
pcDNA5/FRT expression vector and co-transfected with pOG44 to generate a stable Flp-In-CHO cell line. 
Mutations within the  A3R were made using the QuikChange Lightening Site-Directed Mutagenesis Kit (Agilent 
Technologies) in accordance with the manufacturer’s instructions. The Nluc-tagged rat  A3R pcDNA3.1 + con-
struct, used in the generation of the stable Nluc-tagged rat  A3R expressing HEK 293 cell line was kindly gifted to 
us by Stephen Hill and Stephen Briddon (University of Nottingham). All oligonucleotides used for mutagenesis 
were designed using the online Agilent Genomics ‘QuikChange Primer Design’ tool (detailed in Stamatis et al.22 
(Table S4)) and purchased from Merck. All constructs were confirmed by in-house Sanger sequencing.
Compounds. Adenosine, NECA, IB-MECA, HEMADO, DPCPX (8-cyclopentyl-1,3-dipropyl-7H-purine-
2,6-dione) and MRS 1220 were purchased from Sigma-Aldrich and dissolved in dimethyl-sulphoxide (DMSO). 
CA200645, a high affinity AR xanthine amine congener (XAC) derivative containing a polyamide linker con-
nected to the BY630 fluorophore, was purchased from HelloBio (Bristol, UK) and dissolved in DMSO. AV039, 
a highly potent and selective fluorescent antagonist of the human  A3R based on the 1,2,4-Triazolo[4,3-a]qui-
noxalin-1-one linked to  BY63039, was kindly gifted to us by Stephen Hill and Stephen Briddon (University of 
Nottingham). PMA was purchased from Sigma-Aldrich. Compounds under investigation were purchased from 
e-molecules and dissolved in DMSO. The concentration of DMSO was maintained to < 1.5% across all experi-
ments (1.26% for all cAMP assays, 1% for pERK1/2 assays and 1.02% or 1.1% for NanoBRET ligand-binding 
experiments using CA200645 or AV039, respectively).
16
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cAMP accumulation assay. For cAMP accumulation  (A2AR and  A2BR) or inhibition  (A1R or  A3R) experi-
ments, cells were harvested and re-suspended in stimulation buffer (PBS containing 0.1% BSA and 25  μM 
rolipram) and seeded at a density of 2000 cells per well of a white 384-well Optiplate and stimulated for 30 min 
with a range of agonist concentrations. In order to allow the  A1R/A3R mediated  Gi/o response to be determined, 
co-stimulation with forskolin, an activator of  AC40, at the indicated concentration (depending on cell line) was 
performed. Testing of potential antagonists was performed in a competition experiment where cells received a 
co-stimulation with forskolin, agonist and compound/DMSO control, without test compound pre-incubation. 
cAMP levels were then determined using a LANCE cAMP kit as described  previously41. In order to reduce 
evaporation of small volumes, the plate was sealed with a ThermalSeal film (Excel Scientific) at all stages.
Phospho‑ERK assay. ERK1/2 phosphorylation was measured using the homogeneous time resolved fluo-
rescence (HTRF) Phospho-ERK (T202/Y204) Cellular Assay Kit (Cisbio Bioassays, Codolet, France) two-plate 
format in accordance with the manufacturer’s instructions.  A3R expressing Flp-In-CHO were seeded at a density 
of 2000 cells per well of a white 384-well Optiplate and stimulated with agonist and test compounds for 5 min at 
37 °C. Plate reading was conducted using a Mithras LB 940 (Berthold technology). All results were normalised 
to 5 min stimulation with 1 μM PMA, a direct protein kinase C (PKC). To determine if the measured pERK1/2 
level was  Gi-mediated, we treated cells with Pertussis toxin (PTX) (Tocris Biosciences) for 16 h at 100 ng/mL 
prior to pERK assay.
Radioligand binding. All pharmacological methods followed the procedures as described in the  literature42. 
In brief, membranes for radioligand binding were prepared from CHO cells stably transfected with hAR sub-
types in a two-step procedure. In the first step, cell fragments and nuclei were removed at 1000×g and then 
the crude membrane fraction was sedimented from the supernatant at 100,000×g. The membrane pellet was 
resuspended in the buffer used for the respective binding experiments and it was frozen in liquid nitrogen and 
stored at – 80 °C. For radioligand binding at the  A1R, 1 nM  [3H]CCPA was used, for  A2AR 10 nM  [3H]NECA 
and for  A3R 1 nM  [3H]HEMADO. Non-specific binding of  [3H]CCPA was determined in the presence of 1 mM 
theophylline and in the case of  [3H]NECA and  [3H]HEMADO 100 μM R-PIA was used. Ki values from competi-
tion experiments were calculated using Prism (GraphPad Software, La Jolla, CA, USA) assuming competitive 
interaction with a single binding site. The curve fitting results (see Fig. 8 and 20) showed  R2 values ≥ 0.99 for all 
compounds and receptors, indicating that the used one-site competition model assuming a Hill slope of n = 1 
was appropriate.
NanoBRET ligand‑binding. Through the use of NanoBRET, real-time quantitative pharmacology of 
ligand-receptor interactions can be investigated in living cells. CA200645, acts as a fluorescent antagonist at 
both  A1R and  A3R with a slow off-rate43. Using an N-terminally NanoLuc (Nluc)-tagged  A3R expressing cell line, 
competition binding assays were conducted. The kinetic data was fitted with the ‘kinetic of competitive binding’ 
 model28 (Motulsky and Mahan, 1984; built into Prism) to determine affinity  (pKi) values and the association rate 
constant  (Kon) and dissociation rates  (Koff) for unlabelled  A3R antagonists. In several cases this model resulted 
in an ambiguous fit (Regression with Prism 8: “Ambiguous”, 2019). We developed a new model which expands 
on the ‘kinetic of competitive binding’ model to accommodate very rapid competitor dissociation, assuming the 
unlabelled ligand rapidly equilibrates with the free receptor. This method allows determination of compound 
affinity  (pKi) from the kinetic data.
In order to identify if the characterised compounds also bound the rat  A3R, we conducted competition bind-
ing assays using Nluc-tagged rat  A3R expressing HEK 293 cells and the fluorescent compound  AV03939 rather 
than xanthine based CA200645, which have previously been reported as inactive at rat  A3R44. For both human 
and rat  A3R experiments, filtered light emission at 450 nm and > 610 nm (640–685 nm band pass filter) was meas-
ured using a Mithras LB 940 and the raw BRET ratio calculated by dividing the 610 nm emission with the 450 nm 
emission. Here, Nluc on the N-terminus of  A3R acted as the BRET donor (luciferase oxidizing its substrate) and 
CA200645/AV039 acted as the fluorescent acceptor. CA200645 was used at 25 nM, as previously  reported26 and 
AV039 was used at 100 nM (pre-determined  KD, 102 ± 7.59 nM). BRET was measured following the addition 
Figure 7.  Pharmacological characterisation of K series of compounds at the rat  A3R. (A) Comparison of the 
residues of the orthosteric binding area in human and rat  A3Rs. (B) Saturation binding experiment with AV039 
with a  KD of 102 ± 7.59 nM. (C) Inhibition of BRET between Nluc and AV039 at the rat  A3R by MRS 1220 and 
K compounds. HEK293 cells stably expressing Nluc-rat  A3R were treated with 100 nM AV039 and increasing 
concentrations of unlabelled compound. The resulting concentration dependent decrease in BRET ratio at 
5 minutes was taken to calculate  pKi through fitting the Cheng-Prusoff  equation59. Each data point represents 
mean ± SEM of n (n = 5 for MRS 1220, K1, K20, K23 and K25, n = 3 for K10, K17, K18 and K32) experiments, 
performed in duplicate. (D) Top and side (E) views of Rat  A3R in complex with K18. Starting pose (carbons 
of the ligand in green), after 100 ns MD simulation (carbons of the ligand in orange). Light blue sticks show 
residues conserved with human  A3R.  M2647.34 most likely hampers K18 binding due to steric hindrance of the 
dichloro-phenyl group. (F) Top and side views (G) of the average structure of rat  A3R in complex with K25 from 
100 ns MD simulations (carbons of the ligand are shown in orange sticks and light blue sticks show residues in 
contact with K25). K25 was docked into the orthosteric site of the rat  A3R using the GoldScore scoring function 
and the highest scoring pose was inserted in a hydrated POPE bilayer. The complexes were subjected to MD 
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of the Nluc substrate, furimazine (0.1 μM). Nonspecific binding was determined using a high concentration of 
unlabelled antagonist, MRS 1220 at 10 nM or 10 μM, for human and rat  A3R, respectively.
Receptor binding kinetics data analysis. Specific binding of tracer vs time data was analysed using the 
Motulsky and Mahan  method28 (built into Prism 8.0) to determine the test compound association rate constant 
and dissociation rate constant. Data were fit to the “Kinetics of competitive binding” equation in Prism 8.0 
(GraphPad Software Inc, San Diego, CA):
where,
[RL]t is specific binding at time t, N the  Bmax, [L] the tracer concentration, [I] the unlabelled competitor com-
pound concentration, k1 the tracer association rate constant, k2 the tracer dissociation rate constant, k3 the 
compound association rate constant and k4 the compound dissociation rate constant.
Data were also analysed using an equation that assumes compound dissociation is too rapid for the dissocia-
tion rate constant to be determined reliably and the fits to the two equations compared (“Kinetics of competi-
tive binding, rapid competitor dissociation”, derived in the Appendix I, Supplementary material). This equation 
assumes rapid equilibration between compound and receptor and consequently provides an estimate of the 
equilibrium binding affinity of the compound (Ki) but not the binding kinetics of the compound. The equation is,
where ρI is fractional occupancy of receptors not bound by L:
and kobs,+ I is the observed association rate of tracer in the presence of competitor, defined as,
The fits to the two equations were compared statistically using a partial F-test in Prism 8.
Pharmacokinetic assessments of K18. Preliminary pharmacokinetic assessments of K18 was out-
sourced to Eurofins Panlabs (Missouri, U.S.A) and including tests for intrinsic clearance (human liver micro-
somes), plasma (human) stability and half-life in PBS. These tests were conducted in duplicate using a single 
concentration of K18 (0.1  μM or 1  μM) using the substrate depletion method. Here, the percentage of K18 
remaining at various incubation times was detected using high-performance liquid chromatography mass spec-
trometry (HPLC–MS). Reference compounds (verapamil, terfenadine and propantheline) were supplied and 
tested alongside K18. The half-life (t1/2) was estimated from the slope (k) of percentage compound remaining 
(In(%K18 remaining)) versus time (t1/2 =—In(2)/k), assuming first order kinetics. The intrinsic clearance  (CLint, 
in μl/min/mg) was calculated according to the following formula:
Data and statistical analysis. All in vitro assay data was analysed using Prism 8.0 (GraphPad software, 
San Diego, CA), with all dose-inhibition or response curves being fitted using a 3-parameter logistic equation 
to calculate response range or  Emax and IC/EC50. Experimental design ensured random distribution of treat-
ments across 96/384-well plates to avoid systematic bias. Agonist stimulation alone was used as an intrinsic 
control across all experiments. Although initial screening of the 50 compounds was blinded, due to limitations 
in resources, it was not possible to perform all of our experiments in a blinded manner. Normalisation was used 
to control for unwanted sources of variation between experimental repeats.
In the rare cases where significant outliers were identified through the ROUT method (performed in Prism 
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Identify outliers”, 2019), these were excluded from data analysis and presentation. Dose-inhibition/dose–response 
curves were normalised to forskolin, expressed as percentage forskolin inhibition for  Gi-coupled  A1R and  A3R 
(1 μM or 10 μM, respectively) or stimulation for  A2AR and  A2BR (100 μM, representing the maximum cAMP 
accumulation of the system), relative to NECA/IB-MECA (agonist allowing comparison across AR subtypes and 
a selective  A3R agonist, respectively). For cAMP experiments on  A3R mutants, data was normalised to 100 μM 
forskolin, representing the maximum cAMP accumulation possible for each cell line. In the case of pERK1/2 
response, normalisation was performed to PMA, a direct PKC activator providing the maximum pERK1/2 level 
of the system.
Schild analysis was performed to obtain  pA2 values (the negative logarithm to base 10 of the molar concen-
tration of an antagonist that makes it necessary to double the concentration of the agonist to elicit the original 
submaximal response obtained by agonist  alone45) for the potential antagonists. In cases where the Schild slope 
did not differ significantly from unity, the slope was constrained to unity giving an estimate of antagonist affin-
ity (pKB).  pA2 and pKB coincide when the slope is exactly unity. Through performing Schild analysis, whereby 
the  pA2 is independent of agonist, we were able to experimentally determine the effect of receptor mutation on 
antagonist binding. The  pA2 values obtained through conducting Schild analysis of K18 at WT and mutant  A3R 
were compared in order to indicate important residues involved in K18 binding. Whereas an increase in the  pA2 
for a particular mutant when compared to WT suggested the antagonist was more potent, a decrease indicated 
a reduced potency.
All experiments were conducted in duplicate (technical replicates) to ensure the reliability of single values. 
The data and statistical analysis comply with the recommendations on experimental design and analysis in 
 pharmacology46. Statistical analysis, performed using Prism 8.0, was undertaken for experiments where the group 
size was at least n = 5 and these independent values used to calculate statistical significance (*p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001) using a one-way ANOVA with a Dunnett’s post-test for multiple comparisons or 
Students’ t-test, as appropriate. Any experiments conducted n < 5 should be considered preliminary. Compounds 
taken forward for further investigation after our preliminary screening (n = 3) were selected based on a high 
mean cAMP accumulation (> 80%).
Computational biochemistry. MD simulations. Preparation of the complexes between human  A3R 
with K5, K17, K18 or MRS 1220 and rat  A3R with K18 or K25 was based on a homology model of  A2AR (see 
Appendix II in Supplementary material) and are detailed in Lagarias et al.21. Each ligand−protein complex was 
embedded in hydrated POPE bilayers. A simulation box of the protein–ligand complexes in POPE lipids, water 
and ions was built using the System Builder utility of Desmond (Desmond Molecular Dynamics System, ver-
sion 3.0; D.E. Shaw Res. New York, 2011; Maest. Interoperability Tools, 3.1; Schrodinger Res. New York, 2012). 
A buffered orthorhombic system in 10 Å distance from the solute atoms with periodic boundary conditions 
was constructed for all the complexes. The MD simulations were performed with Amber14 and each complex-
bilayer system was processed by the LEaP module in AmberTools14 under the AMBER14 software  package47. 
Amber ff14SB force field  parameters48 were applied to the protein, lipid14 to the lipids, GAFF to the  ligands49 
and  TIP3P50 to the water molecules for the calculation of bonded, vdW parameters and electrostatic interac-
tions. Atomic charges were computed according to the RESP  procedure51 using  Gaussian0352 and antechamber 
of  AmberTools1447. The temperature of 310 K was used in MD simulations in order to ensure that the membrane 
state is above the main phase transition temperature of 298 K for POPE  bilayers53. In the production phase, the 
relaxed systems were simulated in the NPT ensemble conditions for 100 ns. The visualization of produced tra-
jectories and structures was performed using the programs  Chimera54 and  VMD55. All the MD simulations were 
run on GTX 1060 GPUs in lab workstations or on the ARIS Supercomputer.
MM-PBSA calculations. Relative binding free energies of the complexes between K5, K17, K18, MRS 1220 and 
 A3R was estimated by the 1-trajectory MM-PBSA  approach56. Effective binding energies (ΔGeff) were computed 
considering the gas phase energy and solvation free energy contributions to binding—see appendix  II21,22.
Nomenclature of targets and ligands. Key protein targets and ligands in this article are hyperlinked to cor-
responding entries in https ://www.guide topha rmaco logy.org, the common portal for data from the IUPHAR/
BPS Guide to  Pharmacology57, and are permanently archived in the Concise Guide to Pharmacology 2017/1858.
Data availability
The data are available from the corresponding authors on reasonable request.
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